Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.

Oral oncology - 1 Dec 2020

Chen Tseng-Cheng, Wu Chen-Tu, Wang Cheng-Ping, Lou Pei-Jen, Ko Jenq-Yuh, Chang Yih-Leong

Abstract excerpt

OBJECTIVE: To determine the tumor genomic, immunologic expression, and risk factors of treatment outcomes for patients with double head and neck squamous cell carcinoma (HNSCC) and esophageal squamous cell carcinoma (ESCC). METHODS: We reviewed patients with double HNSCC and ESCC between 1995 and 2014. The TP53 genomic mutation, CD8+ tumor infiltrating lymphocytes (TIL) and tumor programmed cell death ligand 1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Esophageal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Esophageal Squamous Cell Carcinoma

Share to Immunity, Cellular

Share to Lymphocytes, Tumor-Infiltrating

Share to Neoplasms, Multiple Primary

Share to Squamous Cell Carcinoma of Head and Neck

Share to Tongue Neoplasms

Source

Identifiers

PMID: 32769036
DOI: 10.1016/j.oraloncology.2020.104945

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.PMID 32769036Read ↗

Comprehensive Genomic and Transcriptomic Analysis of Three Synchronous Primary Tumours and a Recurrence from a Head and Neck Cancer Patient.Semantic proximity Read ↗

Why responses to immune checkpoint inhibitors are heterogeneous in head and neck cancers: Contributions from tumor-intrinsic and host-intrinsic factorsSemantic proximity Read ↗

Correlate the TP53 Mutation and the HRAS Mutation with Immune Signatures in Head and Neck Squamous Cell CancerSemantic proximity Read ↗

Comparison of Somatic Mutations in Primary Squamous Cell Carcinomas of the Hypopharynx and the Esophagus Developed in Individual Patients.Semantic proximity Read ↗

Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patientsSemantic proximity Read ↗

TP53 mutation-associated immunosignatures impact on anti-PD-L1 treatment response in head and neck cancer patients.Semantic proximity Read ↗

Separating distant recurrences from second primaries in head and neck squamous cell carcinomas - A DAHANCA group analysis on paired tumor samples.Semantic proximity Read ↗

The immunologic landscape of HRAS-mutant head and neck squamous-cell carcinomaSemantic proximity Read ↗

Multicentric human papillomavirus-associated head and neck squamous cell carcinoma.Semantic proximity Read ↗

Clonal relationship of synchronous head and neck cancer and esophageal cancer assessed by single nucleotide polymorphism-based loss of heterozygosity analysis.Semantic proximity Read ↗

Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers: The Early Experience of Two Academic CenterSemantic proximity Read ↗

Genetic variants of the p53 and p73 genes jointly increase risk of second primary malignancies in patients after index squamous cell carcinoma of the head and neck.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.